The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1435
Certolizumab Pegol (Cimzia) and Ustekinumab (Stelara) for Psoriatic Arthritis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Certolizumab pegol (Cimzia – UCB), a tumor necrosis factor (TNF) inhibitor previously approved for treatment of Crohn's disease1 and rheumatoid arthritis2, and ustekinumab (Stelara – Janssen), a human interleukin-12 and -23 antagonist previously approved for treatment of moderate-to-severe plaque psoriasis3, have now been approved by the FDA for treatment of active psoriatic arthritis.

STANDARD TREATMENT — NSAIDs may be tried first for treatment of psoriatic arthritis, particularly for mild disease. Methotrexate is generally used for treatment of moderate-to-severe disease. If there is minimal improvement or toxicity after 12-16 weeks of methotrexate treatment, a TNF inhibitor is often added or substituted.

TNF inhibitors appear to be the most effective treatment available to date ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Certolizumab Pegol (Cimzia) and Ustekinumab (Stelara) for Psoriatic Arthritis
Article code: 1435b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian